Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | NPC1 | O15118 | 8/20 | 0.51 |
| ▸ | RAB9A | P51151 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13509560 | 0.87 | ALDH1A1 (0.51) | KDM4EALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL1794300 | 0.82 | ALDH1A1 (0.67) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11808296 | 0.81 | ALDH1A1 (0.61) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13214845 | 0.81 | ALDH1A1 (0.61) | KDM4EALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL15678812 | 0.81 | KDM4E (0.61) | KDM4EALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL5746898 | 0.81 | ALDH1A1 (0.65) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5746890 | 0.81 | ALDH1A1 (0.65) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2521419 | 0.80 | KDM4E (1.00) | KDM4EALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL30947375 | 0.80 | KDM4E (1.00) | KDM4EALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL30863308 | 0.80 | KDM4E (1.00) | KDM4EALDH1A1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0454511-B1 | N-substituted heterocycle derivatives, their preparation, compositions containing them | SANOFI SA (FR) | 1998-06-17 | — | — | EP | claimed |
| US-9757375-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-12 | — | — | US | disclosed |
| US-20150313898-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-9073896-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140113891-A1 | Compounds that inhibit human DNA ligases and methods of treating cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-04-24 | — | — | US | disclosed |
| US-8445537-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | STC.UNM (US) | 2013-05-21 | — | — | US | disclosed |
| EP-1479397-B1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2011-06-08 | — | — | EP | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| EP-0454511-B1 | N-substituted heterocycle derivatives, their preparation, compositions containing them | SANOFI SA (FR) | 1998-06-17 | — | — | EP | disclosed |
| EP-0680481-B1 | DERIVATES OF AZAANTHRAQUINONE AND AZAXANTHONE, HERBICIDES AND PLANT GROWTH REGULATORS CONTAINING THE SAME | BASF AG (DE) | 1998-04-01 | — | — | EP | disclosed |
| EP-0680481-A1 | DERIVATES OF AZAANTHRAQUINONE AND AZAXANTHONE, HERBICIDES AND PLANT GROWTH REGULATORS CONTAINING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994017070-A1 | DERIVATES OF AZAANTHRAQUINONE AND AZAXANTHONE, HERBICIDES AND PLANT GROWTH REGULATORS CONTAINING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 1994-08-04 | — | — | WO | disclosed |
| US-3931205-A | ANTIRHEUMATIC, ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JA) | 1976-01-06 | — | — | US | disclosed |
| US-3931199-A | ANTIALLERGY | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JA) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313898-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | LIG1, LIG4, LIG3 | KDM4E 1696/4885ALDH1A1 2436/4885NPC1 3302/4885 |
| US-20140113891-A1 | Compounds that inhibit human DNA ligases and methods of treating cancer | LIG1, LIG4, LIG3 | KDM4E 1696/4885ALDH1A1 2436/4885NPC1 3302/4885 |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | KCNT1, KCNMA1, KCNJ2 | KDM4E 262/4885ALDH1A1 2383/4885NPC1 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.